Evidence map›Paper›PMID 32382329›Full record

ArticleOncology letters2020

Prognostic value of quantitative FDG-PET in the prediction of survival and local recurrence for patients with advanced oral cancer treated with superselective intra-arterial chemoradiotherapy.

Tomoyuki Oyama, Yoichiro Hosokawa, Kazuki Abe, Kazuki Hasegawa, Roman Fukui, Masahiko Aoki, Wataru Kobayashi

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tomoyuki OyamaFaculty of Graduate School of Biomedical Sciences and Engineering, Hokkaido University, Hokkaido 061-0293, Japan.
Yoichiro HosokawaDepartment of Radiation Science, Graduate School of Health Sciences, Hirosaki University, Aomori 036-8564, Japan.
Kazuki AbeFaculty of Graduate School of Biomedical Sciences and Engineering, Hokkaido University, Hokkaido 061-0293, Japan.
Kazuki HasegawaDepartment of Radiation Science, Graduate School of Health Sciences, Hirosaki University, Aomori 036-8564, Japan.
Roman FukuiDepartment of Radiation Science, Graduate School of Health Sciences, Hirosaki University, Aomori 036-8564, Japan.
Masahiko AokiDepartment of Radiology and Radiation Oncology, Graduate School of Medicine, Hirosaki University, Aomori 036-8562, Japan.
Wataru KobayashiDepartment of Oral and Maxillofacial Surgery, Graduate School of Medicine, Hirosaki University, Aomori 036-8562, Japan.
Hirosaki University · JPHokkaido University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study aimed to evaluate the relationship between 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) standardized uptake value (SUV) [pre-treatment SUV (pre-SUV) and post-treatment SUV (post-SUV)] and treatment results in patients with advanced oral cancer treated with superselective intra-arterial chemoradiotherapy (SSIACRT). A total of 37 patients with advanced oral cancer were treated with SSIACRT. The treatment consisted of superselective intra-arterial chemotherapy (docetaxel (DOC) 40 mg/mm

Indexed as

18F-Fluorodeoxyglucose positron emission tomography with computed tomographyadvanced oral cancerlocal recurrenceradiation therapysuperselective intra-arterial chemotherapy

Identifiers

PMID32382329
PMCPMC7202323
OpenAlexW3013262481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.